{"name":"Voyager Therapeutics, Inc.","slug":"voyager","ticker":"VYGR","exchange":"NASDAQ","domain":"voyagertherapeutics.com","description":"Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.","hq":"Lexington, MA","founded":0,"employees":"141","ceo":"Alfred Sandrock","sector":"Biotech","stockPrice":4.29,"stockChange":0.14,"stockChangePercent":3.37,"marketCap":"$260M","metrics":{"revenue":36494000,"revenueGrowth":-59.9,"grossMargin":-243.5,"rdSpend":0,"netIncome":-116637000,"cash":141479008,"dividendYield":0,"peRatio":-2.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-23","type":"earnings","headline":"Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Voyager Therapeutics reported its fourth quarter and full year 2022 financial results, with a net loss of $34.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-06-01","type":"deal","headline":"Voyager Therapeutics Announces Collaboration with the Michael J. Fox Foundation for Parkinson's Research","summary":"Voyager Therapeutics announced a collaboration with the Michael J. Fox Foundation for Parkinson's Research to advance the development of its gene therapy program for Parkinson's disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBNRURocTYyODUyRkl2cndXMFpZVVdBMXYzdWdCYXZhTmEtTjdnanJTbU11WExiWFcxcTZQWWh5elJOdkkzZ0RIZGxTdGZWRjgxeGlMME1LR3gtZlViSC1QTE01cXZNaWttaE11N3ZR?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Voyager Therapeutics Inc (VYGR) - Stock Titan","headline":"If You Invested $1,000 in Voyager Therapeutics Inc (VYGR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxNNHppcTlmYldTazVFOTVtd1FjVGRwamUyNG14SFJ5MjhKVG9iX2tSMEZvNnNKbUxoS3VRd1RqREp0RTNoZVM2Q240NkRjWUFRODlKbVNVWXlwRUktUkNkRFluY0o3c1BsS01HWjZGR2pJRVlNbnBldzMwUzh1WEpuUm5vdERKejBQb0NNSWVfMjJacldNU2VhNVBVa0dZTHByWTM1MXdxLXJHdFZ1SncyQmV2OUtWNllTMldLT1lRN0drUjQwZFZrb1NpbE44eHNrcS1QbGdtWmpEMU5qOVc0OEdTcDNPZHctOTVVdm9HNV9kVnE5WFdISGt3dnc3ZE1FdzAzekV0UXgya2lEY1E0VElWTUczdw?oc=5","date":"2026-02-05","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-15","type":"pipeline","source":"simplywall.st","summary":"Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet - simplywall.st","headline":"Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-14","type":"earnings","source":"simplywall.st","summary":"Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st","headline":"Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPd04weE1UZEdpOS1SdUZlTmd5MTQ0VUtSQUdOQXJtZFloWnppbDNrY1YwZXBZaURzUmktQkh0TVRPWXJHQ2wwM2lKLUpDMm5CTEZBeTlRWVkzWDdJa2VhbVNnVWs4Y2kwNnEyM3RDUmNCVGxrRDhRNHlOSWpHN2JCNlJvWDAxS1VsWXhSUkhMVVNzSk92dTVUNm9PN1VGdWJqbjl1MDF3VHotazJadVhEYg?oc=5","date":"2025-06-06","type":"pipeline","source":"Seeking Alpha","summary":"Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade) - Seeking Alpha","headline":"Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-27","type":"pipeline","source":"simplywall.st","summary":"It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year - simplywall.st","headline":"It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxObVA3S3JTR056UzNLUEd2OTNfOVdOVWxzUmdfOWFSWmtyX1BQNG5hZEs2NExJZG4tWkRvd1Fjd09vUnRpaWpBWXNIWWlFSEtJQUNGNHo4Q0JIcElibk5rZkIteVBrZW9ZMVA2eVVUS2ZBbVdQVHRFd1ZhS3FWOEktWkFVVlB1Skpz?oc=5","date":"2025-02-12","type":"pipeline","source":"Yahoo Finance","summary":"Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now - Yahoo Finance","headline":"Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZWpub0g0dGE2dFBTMGltZFNZVVExb3dYRjdRandESm04QVNkY2RKbndIaG9rcHV4NFN2bTVPV2hzWFZqNHdiR3k5Mk1ma3V3NGF0a2V3aXI5T3ZrVC1sa2VLZ2h0UG9ibmhhQUpJdFlfeTJJcDBnbXcydm9WVEtEQXZULXVVQVRJ?oc=5","date":"2025-01-30","type":"deal","source":"Yahoo Finance","summary":"What Makes Voyager Therapeutics (VYGR) a New Buy Stock - Yahoo Finance","headline":"What Makes Voyager Therapeutics (VYGR) a New Buy Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQQWxvbnRibDBUcTd6c3kxQkxnS29KdE84LXhlNVQ5aWFRZmJMaFJfYmxjSGo0eGRNZnpOaW9MLWpaRTlKd3ZsOWZKS0dzdW01aWJZT2pBVE5sWEVadzh3QmVkakFTOWFqbW8xOWY5LVhCY3FQZ0phSkYyNU5aY1NzQmx0ZzZvb1RicDIybGdrbUxDaFVJUTZZSU50OFExRUc1YkZyaXNoRUhvcEN6ZURkb0RSd2l5TnRONzlIdnVYTQ?oc=5","date":"2024-03-08","type":"pipeline","source":"Seeking Alpha","summary":"Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier - Seeking Alpha","headline":"Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE8zemRlSVVIdXdkWVJBXzZNZXJwNThmSWQ5VFhqd2hTRkh5YWxGeXEtbkdlOW1ZVG5PUm9SRUR0MDNVREU3clNuWHRXT1dKRFlh?oc=5","date":"2024-01-02","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPX2VxcExSWXZnZUp0c0UyaTdQVDlUUmplZVlOUUJBeWRHcl95NnhnV3A0cUpiVW1PZTdmeXJ3d0dxUWJWLXlZWVdSbDE4V2M0UzJqd3NBUGlvTnVNeXpTSmNnUFdMaktxWXpvOUs5ZHJSVzJGZFgyWGdxZDYzOHhtTzlUWWtJN21NbnFHRnh5S0VpRkxYRFdKN2EwZW82T1piME9XNndBUnJFS3dKS21RM2tyd2N4MTdlSElhZFdRYw?oc=5","date":"2023-12-04","type":"deal","source":"Seeking Alpha","summary":"Voyager Therapeutics' Strategic Partnerships And TRACER Technology - Speculative Buy - Seeking Alpha","headline":"Voyager Therapeutics' Strategic Partnerships And TRACER Technology - Speculative Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOam1Mc3E1QXpDVlgwUkVIV3J6RkF0OWZEb01wRVVxZWhPWTlfZ3cxMno3RmpvRVdlX25uUGJIczFhZjNfdW92eXpCUXU3LXVQN2NPb05lSXR6S0VZLWJ3alRRWFNwSS1PZTN6MEktT1lPWU1OQ0Y3RFU4Qnk1bDh6bjl0MW5wUU5PQkFSV3kyOTRIZ1FKSlV1NnFZSDE2UFI4YWxjTDNpNjFLZw?oc=5","date":"2023-08-07","type":"pipeline","source":"citybiz","summary":"Voyager Therapeutics Appoints Beth Shafer as Chief Business Officer - citybiz","headline":"Voyager Therapeutics Appoints Beth Shafer as Chief Business Officer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["uniQure","Spark Therapeutics","Avalyn Pharma"],"therapeuticFocus":["Huntington's disease","Parkinson's disease"],"financials":{"source":"yahoo_finance","revenue":40374000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":40374000},{"period":"2024-12-31","value":80001000},{"period":"2023-12-31","value":250008000},{"period":"2022-12-31","value":40907000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":134674000,"rdSpendHistory":[{"period":"2025-12-31","value":134674000},{"period":"2024-12-31","value":127368000},{"period":"2023-12-31","value":92172000},{"period":"2022-12-31","value":60764000}],"sgaSpend":37544000,"operatingIncome":-131844000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-131844000},{"period":"2024-12-31","value":-83287000},{"period":"2023-12-31","value":122014000},{"period":"2022-12-31","value":-50837000}],"netIncome":-119721000,"netIncomeHistory":[{"period":"2025-12-31","value":-119721000},{"period":"2024-12-31","value":-65002000},{"period":"2023-12-31","value":132330000},{"period":"2022-12-31","value":-46408000}],"eps":-1.13,"epsHistory":[{"period":"2024-12-31","value":-1.13},{"period":"2023-12-31","value":2.97},{"period":"2022-12-31","value":-1.21},{"period":"2021-12-31","value":-1.89}],"cash":65300000,"cashHistory":[{"period":"2025-12-31","value":65300000},{"period":"2024-12-31","value":71367000},{"period":"2023-12-31","value":68802000},{"period":"2022-12-31","value":98959000}],"totalAssets":252281000,"totalLiabilities":56200000,"totalDebt":36499000,"equity":196081000,"operatingCashflow":-132467000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-132467000},{"period":"2024-12-31","value":-15310000},{"period":"2023-12-31","value":77919000},{"period":"2022-12-31","value":-12509000}],"capex":-2596000,"capexHistory":[{"period":"2025-12-31","value":-2596000},{"period":"2024-12-31","value":-3521000},{"period":"2023-12-31","value":-3256000},{"period":"2022-12-31","value":-2491000}],"freeCashflow":-135063000,"dividendsPaid":null,"buybacks":null,"employees":141,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8261000,"ebit":-30270000,"ebitda":-29338000,"period":"2026-03-31","revenue":2593000,"epsBasic":-0.47,"netIncome":-27937000,"rdExpense":24602000,"epsDiluted":-0.47,"grossProfit":null,"operatingIncome":-30270000},{"sga":9316000,"ebit":-29932000,"ebitda":-28883000,"period":"2025-12-31","revenue":15336000,"epsBasic":-0.47,"netIncome":-27426000,"rdExpense":35952000,"epsDiluted":-0.47,"grossProfit":null,"operatingIncome":-29932000},{"sga":8093000,"ebit":-30594000,"ebitda":-29662000,"period":"2025-09-30","revenue":13365000,"epsBasic":-0.47,"netIncome":-27892000,"rdExpense":35866000,"epsDiluted":-0.47,"grossProfit":null,"operatingIncome":-30594000},{"sga":10495000,"ebit":-36625000,"ebitda":-35560000,"period":"2025-06-30","revenue":5200000,"epsBasic":-0.57,"netIncome":-33382000,"rdExpense":31330000,"epsDiluted":-0.57,"grossProfit":null,"operatingIncome":-36625000},{"sga":9640000,"ebit":-34693000,"ebitda":-33679000,"period":"2025-03-31","revenue":6473000,"epsBasic":-0.53,"netIncome":-31021000,"rdExpense":31526000,"epsDiluted":-0.53,"grossProfit":null,"operatingIncome":-34693000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.29,"previousClose":4.15,"fiftyTwoWeekHigh":5.55,"fiftyTwoWeekLow":2.65,"fiftyTwoWeekRange":"2.65 - 5.55","fiftyDayAverage":4.03,"twoHundredDayAverage":4.06,"beta":1.26,"enterpriseValue":143835344,"forwardPE":-2.8,"priceToBook":1.29,"priceToSales":7.11,"enterpriseToRevenue":3.94,"enterpriseToEbitda":-1.2,"pegRatio":0,"ebitda":-119943000,"ebitdaMargin":0,"freeCashflow":-80829624,"operatingCashflow":-127991000,"totalDebt":34566000,"debtToEquity":19.9,"currentRatio":8.42,"returnOnAssets":-27.1,"returnOnEquity":-52.3,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":14.89,"targetHighPrice":25,"targetLowPrice":8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":15.1,"institutionHeldPercent":59,"sharesOutstanding":60421287,"floatShares":39774125,"sharesShort":3663210,"shortRatio":6.84,"shortPercentOfFloat":6.1,"epsTrailing":-1.98,"epsForward":-1.55,"revenuePerShare":0.62,"bookValue":3.32,"officers":[{"age":67,"name":"Dr. Alfred W. Sandrock Jr., M.D., Ph.D.","title":"President, CEO & Director"},{"age":54,"name":"Ms. Robin  Swartz","title":"Principal Financial Officer, Treasurer, Chief Business Officer & COO"},{"age":null,"name":"Dr. Krystof  Bankiewicz M.D., Ph.D.","title":"Founder"},{"age":66,"name":"Dr. Mark A. Kay M.D., Ph.D.","title":"Founder"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.voyagertherapeutics.com","phone":"857 259 5340"}}